Mindray raises FY13 guidance in spite of “mixed bag” Q2
This article was originally published in Clinica
Executive Summary
Mindray Medical, one of China’s largest homegrown medtech companies, has put out what analysts deem to be a patchy performance in the second quarter this year. Nonetheless, this did not stop the firm from raising its outlook for full-year revenue growth, which it now expects to be 18%, up from its previous guidance of 17%.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.